This clinical practice guideline has been prepared by the Working Group on Problematic Substance Use in Pregnancy, reviewed by the Maternal Fetal Medicine Committee, the Family Physicians Advisory Committee and the Medico-Legal Committee, and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.
The literature searches and bibliographic support for this guideline were undertaken by Becky Skidmore, Medical Research Analyst, Society of Obstetricians and Gynaecologists of Canada.
Disclosure statements have been received from all members of the committees.
Dr Alice Ordean received funding from National Institute on Drug Abuse grant R01 DA015741.
This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.